Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Endocr Pract. 2011 Mar-Apr;17 Suppl 1:18-25. doi: 10.4158/EP10302.RA.
To provide a clinical update on the management of hypoparathyroidism with focus on postsurgical hypoparathyroidism.
Using PubMed, English-language literature was searched related to management of hypoparathyroidism after thyroid and parathyroid surgery. We discuss the incidence, pathophysiology, differential diagnosis, early diagnosis, and treatment of transient and permanent hypoparathyroidism.
Hypoparathyroidism is a well-recognized complication after thyroid and parathyroid surgery. Transient hypoparathyroidism occurs in 10% of patients who undergo total thyroidectomy. Less than half of patients who develop transient hypoparathyroidism after thyroid surgery develop permanent hypoparathyroidism. Postsurgical hypocalcemia resulting from inadequate parathyroid hormone (PTH) secretion could cause neurologic complications and respiratory compromise. Calcium supplements and vitamin D analogues effectively treat hypocalcemia associated with postsurgical hypoparathyroidism. Measurement of PTH after thyroid and parathyroid surgery allows early identification of patients likely to require calcium supplements and vitamin D analogue therapy. Early identification and appropriate management of postsurgical hypoparathyroidism prevent hypocalcemia-related complications and allow patients to be discharged from the hospital earlier. Patients who develop permanent hypoparathyroidism should receive appropriate follow-up care to monitor for long-term complications related to supplemental therapy. PTH replacement therapy is currently being evaluated for the treatment of transient and permanent hypoparathyroidism.
A multidisciplinary approach involving an endocrinologist and surgeon is imperative to reduce the morbidity associated with hypoparathyroidism after thyroid and parathyroid surgery. Supplemental therapy with calcium and vitamin D analogues is standard. New drugs currently in clinical trials offer promising treatment options.
提供关于甲状旁腺功能减退症管理的临床更新,重点是手术后甲状旁腺功能减退症。
使用 PubMed 检索了与甲状腺和甲状旁腺手术后甲状旁腺功能减退症管理相关的英文文献。我们讨论了暂时性和永久性甲状旁腺功能减退症的发病率、病理生理学、鉴别诊断、早期诊断和治疗。
甲状旁腺功能减退症是甲状腺和甲状旁腺手术后的一种公认的并发症。10%的甲状腺全切除术患者发生暂时性甲状旁腺功能减退症。甲状腺手术后发生暂时性甲状旁腺功能减退症的患者中,不到一半会发展为永久性甲状旁腺功能减退症。甲状旁腺激素(PTH)分泌不足引起的手术后低钙血症可导致神经并发症和呼吸窘迫。钙补充剂和维生素 D 类似物可有效治疗与手术后甲状旁腺功能减退症相关的低钙血症。甲状腺和甲状旁腺手术后测量 PTH 可早期识别可能需要钙补充剂和维生素 D 类似物治疗的患者。早期识别和适当的手术后甲状旁腺功能减退症管理可预防低钙血症相关并发症,并使患者更早出院。发生永久性甲状旁腺功能减退症的患者应接受适当的随访,以监测与补充治疗相关的长期并发症。目前正在评估 PTH 替代疗法治疗暂时性和永久性甲状旁腺功能减退症。
涉及内分泌科医生和外科医生的多学科方法对于降低甲状腺和甲状旁腺手术后甲状旁腺功能减退症相关发病率至关重要。钙和维生素 D 类似物的补充治疗是标准的。目前正在临床试验中的新药提供了有前途的治疗选择。